Sugi Predict

Sugi Predict / Compounds / SCHEMBL457160

SCHEMBL457160

SCHEMBL457160

PCCCC(C12CC3CC(CC(C3)C1)C2)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC22A2 O15244 1/20 0.37
▸ SLC47A1 Q96FL8 1/20 0.37
▸ MAPT P10636 1/20 0.35
▸ EPHX2 P34913 4/20 0.35
▸ NPC1 O15118 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ GRIN2D O15399 2/20 0.30
▸ GRIN3B O60391 2/20 0.30
▸ GRIN1 Q05586 2/20 0.30
▸ GRIN2A Q12879 2/20 0.30
▸ GRIN2B Q13224 2/20 0.30
▸ GRIN2C Q14957 2/20 0.30
▸ GRIN3A Q8TCU5 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL1478375 0.98 SLC22A2 (0.35) SLC22A2SLC47A1MAPTEPHX2NPC1
SCHEMBL3285298 0.92 EPHX2 (0.36) SLC22A2SLC47A1MAPTEPHX2NPC1
SCHEMBL3282755 0.92 EPHX2 (0.36) SLC22A2SLC47A1MAPTEPHX2NPC1
SCHEMBL23111395 0.86 SLC22A2 (0.39) SLC22A2SLC47A1MAPTEPHX2NPC1
SCHEMBL16908469 0.78 EPHX2 (0.33) EPHX2ALDH1A1
SCHEMBL2927660 0.77 SLC22A2 (0.42) SLC22A2SLC47A1MAPTEPHX2NPC1
SCHEMBL6346242 0.73 SLC22A2 (0.39) SLC22A2SLC47A1MAPTEPHX2NPC1
SCHEMBL9282423 0.73 SLC22A2 (0.39) SLC22A2SLC47A1MAPTEPHX2NPC1
SCHEMBL1324024 0.72 — —
SCHEMBL23930359 0.67 SLC22A2 (0.32) SLC22A2SLC47A1MAPTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115745884-B Opioid derivatives, intermediates and process for preparing the same 绍兴赜军生物医药科技有限公司 2025-06-13 — — CN claimed
CN-118994178-A General intermediate of opioid derivatives, preparation method and application thereof 绍兴赜军生物医药科技有限公司 2024-11-22 — — CN claimed
WO-2024235322-A1 VERSATILE INTERMEDIATE FOR OPIOID DERIVATIVES, AND PREPARATION METHOD THEREFOR AND USE THEREOF 绍兴赜军生物医药科技有限公司 2024-11-21 — — WO claimed
WO-2024199209-A1 METHOD FOR SYNTHESIZING KEY INTERMEDIATE OF SELECTIVE THR ΒETA AGONIST 西藏海思科制药有限公司 2024-10-03 — — WO claimed
CN-114573508-B Oxycodone compound, intermediate and preparation method thereof 绍兴赜军生物医药科技有限公司 2024-07-23 — — CN claimed
CN-117881670-A Methods of making EGFR inhibitors 缆图药品公司 2024-04-12 — — CN claimed
CN-109694350-B Compound containing fluoromethyl and preparation method thereof 中国科学院上海有机化学研究所 2023-05-09 — — CN claimed
CN-109912455-B Method for preparing 4-hydroxy-4' -cyanobiphenyl 宁夏中星显示材料有限公司 2022-03-01 — — CN claimed
US-8119800-B2 Processes for preparing HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-02-21 — — US claimed
US-20090163712-A1 PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-06-25 — — US claimed
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 — — US disclosed
US-20260034126-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-02-05 — — US disclosed
US-12528816-B2 Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors CARDURION PHARMACEUTICALS, INC. (US) 2026-01-20 — — US disclosed
EP-4660192-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2025-12-10 — — EP disclosed
US-12473384-B2 Cyclopentadienyl/adamantyl phosphinimine titanium complexes NOVA CHEMICALS (INTERNATIONAL) S.A. (CH) 2025-11-18 — — US disclosed
EP-1982979-B1 Manufacture of polyisocyanates containing uretdione groups BAYER MATERIALSCIENCE AG (DE) 2010-01-27 — — EP disclosed
US-20090163712-A1 PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-06-25 — — US disclosed
US-20080262262-A1 Preparation of polyisocyanates containing uretdione groups using phosphine catalysts BAYER MATERIALSCIENCE AG 2008-10-23 — — US disclosed
EP-1982979-A1 Manufacture of polyisocyanates containing uretdione groups Bayer MaterialScience AG (DE) 2008-10-22 — — EP disclosed
WO-2007115685-A1 METHOD FOR PRODUCING BIPHENYLAMINES FROM VINYL ANILINES BAYER CROPSCIENCE AG (DE) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528816-B2 Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors RYR2, CACNA1C, CAMK4 SLC22A2 2865/4885SLC47A1 2412/4885MAPT 4344/4885
US-20080262262-A1 Preparation of polyisocyanates containing uretdione groups using phosphine catalysts PPIP5K2, IPMK, INPP5B SLC22A2 3523/4885SLC47A1 4552/4885MAPT 1959/4885
US-20260034126-A1 KRAS INHIBITORS KRAS, NRAS, HRAS SLC22A2 2398/4885SLC47A1 2478/4885MAPT 4877/4885
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 SLC22A2 3601/4885SLC47A1 2944/4885MAPT 4456/4885
US-20090163712-A1 PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS POLB, POLR2E, POLR2H SLC22A2 3098/4885SLC47A1 2570/4885MAPT 2934/4885
US-12473384-B2 Cyclopentadienyl/adamantyl phosphinimine titanium complexes ACP1, CCT7, TCP1 SLC22A2 4848/4885SLC47A1 3983/4885MAPT 3308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.